BioLineRX (BLRX)

• Market cap: $15.1M
• 1 day: -7.79%
• 5 days: -10.13%
• 1 month: -14.66%
• 3 months: -3.53%
• 6 months: 2.60%
• Year to date: -65.26%
• 1 year: -87.64%
• 5 years: -95.56%
• 10 years: -99.54%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

928% more call options, than puts

Call options by funds: $596K | Put options by funds: $58K

798% more capital invested

Capital invested by funds: $28K [Q1] → $251K (+$223K) [Q2]

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

36% more funds holding

Funds holding: 11 [Q1] → 15 (+4) [Q2]

1.29% more ownership

Funds ownership: 0% [Q1] → 1.29% (+1.29%) [Q2]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 238% upside
• Avg. target: $19 435% upside
• High target: $26 632% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis	632% upside $26	Buy Reiterated	17 Jun 2025
Jones Trading Justin Walsh	238% upside $12	Buy Upgraded	30 May 2025